CN102831322B - A kind of method of evaluation mark thing level - Google Patents
A kind of method of evaluation mark thing level Download PDFInfo
- Publication number
- CN102831322B CN102831322B CN201210313089.8A CN201210313089A CN102831322B CN 102831322 B CN102831322 B CN 102831322B CN 201210313089 A CN201210313089 A CN 201210313089A CN 102831322 B CN102831322 B CN 102831322B
- Authority
- CN
- China
- Prior art keywords
- group
- label
- level
- experimental group
- evaluation mark
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to a kind of analysis of evaluation mark thing, particularly relate to the method for the higher evaluation mark thing level of a kind of accuracy.The method of a kind of evaluation mark of the present invention thing level is by under different study conditions, detect the data of each label factor of influence in abnormal group and control group in each experimental group, and meta-analysis is carried out to the data of aforementioned collection, contrast the heterogeneity of each label factor of influence under different study condition and conspicuousness situation, calculate the evaluation number of each label level.Better reliability of the present invention, accuracy are higher, can be used for the field such as environmental monitoring, chemical analysis.
Description
Technical field
The present invention relates to a kind of analysis of evaluation mark thing, particularly relate to the method for the higher evaluation mark thing level of a kind of accuracy.
Background technology
Artificial joint replacement is huge advance for the intractable joint disease of solution, and amount for surgical is increasing year by year, but the generation of postoperative complications is finally sought help from skeleton animation art and made up.The topmost reason of current joint prosthesis failure is aseptic loosening, so control joint mobilization overhauls number of times for minimizing, extends the prosthese life-span significant.Artificial joint prosthesis is inserted after in body, the destruction that periprosthetic bone absorbs, bone dissolving can cause prosthese supporting structure, when this destruction runs up to a certain degree, joint prosthesis stability will be caused to decline and prosthetic loosening.Can cause except the dissolving of Periprosthetic bone except infecting, topmost reason is the chronic inflammatory reaction that wear particle induction produces and bone solubilizing reaction.Imaging examination contributes to the determination of bone soluble end and the diagnosis of prosthetic loosening, but because the complicacy of joint anatomy and Metallic orthopaedic implants are for the impact of the quality of image, cause the resolution characteristic of imaging examination to Periprosthetic region limited, detection sensitivity and heterogeneity are not high.
Except traditional clinical manifestation and x-ray take the photograph sheet, aseptic loosening of prosthesis exploitation of still needing possesses good sensitivity and specific diagnostic means, requires to reduce the radiological hazard to human body simultaneously.From the beginning of the nineties in last century, existing numerous biomarker or cell factor find relevant with the morbidity of aseptic loosening, and the research that these responsive and harmless biomarkers detect for aseptic loosening is in recent years significantly increased.But, due to the impact of the various factors such as detection means, testing environment, causing each literature research result to occur deviation, therefore, in order to carry out the evaluation of label level more accurately, needing to find new method.
Summary of the invention
For above-mentioned Problems existing, present invention is disclosed a kind of method of evaluation mark thing level, mainly by detecting label horizontal data in abnormal group and control group, the actual variance of the same label of comparative analysis in different research object.
The object of the invention is to be achieved through the following technical solutions:
A method for evaluation mark thing level, wherein, comprises the following steps:
Step 1: determine label kind to be evaluated;
Step 2: multiple experimental group is set, each experimental group all selects abnormal group and control group as research object;
Step 3: the marker data gathering research object described in multiple experimental group; Setting the level of each marker data in abnormal group in each experimental group is X
1be X with the level in control group
2;
Step 4: the marker data of the exception group in described each experimental group and control group is carried out the test with statistical significance number of times, averages respectively and obtain
with
and calculate standard error SEM respectively
1and SEM
2, merge described standard deviation, computing formula is
Step 5: calculate the standardization difference in means SMD at abnormal group and control group of each label factor of influence in each experimental group, computing formula is
Step 6: use I
2the method of statistic calculates the heterogeneous difference I of each label level between different experiments group
2;
Step 7: the evaluation number DI calculating each label level, computing formula is DI=|SMD|-I
2.
The method of above-mentioned evaluation mark thing level, wherein, in described step 2, experimental group is preferably at least 2 groups.
The method of above-mentioned evaluation mark thing level, wherein, for analyzing the standardization difference in means SMD at abnormal group and control group of each label factor of influence in each experimental group under random-effect model in described step 5.
The method of above-mentioned evaluation mark thing level, wherein, in described step 7, DI is less than 0 for low value, is more than or equal to 0 and is less than or equal to 1 for medium value, being greater than 1 for high value.
Those skilled in the art are it is understood that the abnormal group of group referring to label level to be detected of the present invention, and control group refers to normal group of label level, and described label refers to material to be detected.
The invention has the beneficial effects as follows by under different study conditions, detect the data of each label factor of influence in abnormal group and control group in each experimental group, and meta-analysis is carried out to the data of aforementioned collection, contrast the heterogeneity of each label factor of influence under different study condition and conspicuousness situation, calculate the evaluation number of each label level.Better reliability of the present invention, accuracy are higher, can be used for the chemical analysis field such as environmental monitoring, pollutant monitoring, drug screening, food and drug safety detection.
Accompanying drawing explanation
Fig. 1 is the schematic flow sheet of the method for evaluation mark thing level of the present invention;
Embodiment
Below in conjunction with the drawings and specific embodiments, the invention will be further described, but not as limiting to the invention.
Shown in composition graphs 1, to detect aseptic loosening of prosthesis relevant biomarkers thing level, the method for a kind of evaluation mark thing level of the present invention, wherein, comprises the following steps:
Step 1: determine label factor of influence kind to be evaluated and quantity;
In a preferred version of the present invention, in this step, the biomarker with good diagnostic value can be selected, as interleukin-11 β, TNF (TNF) α, interleukin 8, NTx N terminal peptide (NTX), 1L-6,1L-1, RANKL, BGP, PGE2, TRAP5b, OPG, OPG/RANKL, PICP, clostridiopetidase A.
Step 2: research object is divided into abnormal group and control group by each experimental group, detects the label factor of influence data of described research object;
Step 3: the label factor of influence data gathering research object described in multiple experimental group; Setting the level of each label factor of influence data in abnormal group in each experimental group is X
1be X with the level in control group
2;
In the present embodiment, adopt the data of existing literature research as experimental result, from in Dec, 2011, our system retrieval Pubmed database, Ovidmedline database, Embase (Embase) and Wanfang Database (in February ,-2012 January nineteen forty-six), filter out 39 sections of cohort studies about aseptic loosening biomarker and (amount to 39 groups of datas, be equivalent to 39 experimental group), research object 1622 example.
The research characteristic of the biomarker that table 1 is relevant to aseptic loosening
Can be found out by table 1, there are differences between the individual label level of existing bibliographical information.
Step 4: the label factor of influence data of the exception group in described each experimental group and control group are carried out the test with statistical significance number of times, averages respectively and obtain
with
and calculate standard error SEM respectively
1and SEM
2, merge described standard deviation, computing formula is
For the meta-analysis result of above-mentioned detection biomarker, in this step, the ReviewManager5.1.2 software of Cochrane is adopted to carry out data statistics.
Step 5: calculate the standardization difference in means SMD at abnormal group and control group of each label factor of influence in each experimental group, computing formula is
Further, in this step, the standardization difference in means SMD at abnormal group and control group of each label factor of influence in each experimental group should be analyzed under random-effect model.
Step 6: use I
2the method of statistic calculates the heterogeneous difference I of each label level between different experiments group
2.
In this step, I
2represent the difference of different experiments group result of study, " I
2=0 " the complete homogeneity of each experimental group result of study is represented, " I
2< 31% " represent that the otherness of each experimental group result of study is not obvious, " I
2> 56% " represent that the otherness of each experimental group result of study is obvious.
Step 7: the evaluation number DI calculating each label level, computing formula is DI=|SMD|-I
2.
The meta-analysis of the biomarker that table 2 is relevant with aseptic loosening
| Label | Experimental group number | Research number of cases | SMD [95% credibility interval] | I 2 | DI |
| IL-6 | 8 | 400 | 0.64[-0.07，1.34] | 89％ | -0.25 |
| IL-1β ＊#& | 6 | 131 | 0.89[0.51，1.26] | 1％ | 0.89 |
| TNF-a ＊#& | 5 | 312 | 0.85[0.51，1.20] | 45％ | 0.40 |
| IL-8 ＊#& | 2 | 300 | 1.24[0.91，1.58] | 42％ | 0.82 |
| RANKL# | 3 | 63 | 0.53[-0.16，1.21] | 40％ | 0.13 |
| NTX ＊#& | 2 | 266 | 0.72[0.39，1.05] | 0％ | 0.72 |
| BGP | 2 | 50 | 1.07[-0.69，2.83] | 73％ | 0.34 |
| PGE 2 ＊ | 3 | 132 | 1.63[0.16，3.11] | 87％ | 0.76 |
| TRAP5b ＊# | 3 | 121 | 1.69[1.18，2.20] | 24％ | 1.45 |
| OPG ＊ | 2 | 135 | 1.69[0.96，2.42] | 61％ | 1.08 |
| OPG/RANKL ratio ＊ | 3 | 134 | -0.68[-1.31，-0.05] | 63％ | 0.05 |
| PICP ＊ | 3 | 130 | -0.64[-1.27，-0.02] | 66％ | -0.02 |
In table 2,
*show that between loosening group and control group, label level difference has conspicuousness, P<0.05.# to show in each group that the heterogeneous difference of different research is remarkable, i.e. P>0.05 and I
2<50%.& shows crater blasting display Data distribution8 almost symmetry after sensitivity analysis, shows without obviously delivering skew.
DI is less than 0 for low value, is more than or equal to 0 and is less than or equal to 1 for medium value, being greater than 1 for high value.Can be used for the meta-analysis of the different diagnostic tests of same research index, carry out the diagnostic value evaluating this research index, also can be used as a kind of evaluation number (Evaluationindex) simultaneously, undertaken evaluating the actual variance of same factor of influence in different research object by comprehensively different research.DI value is higher, illustrates that label reference value is larger.
Although in the above embodiment of the present invention, to detect aseptic loosening of prosthesis relevant biomarkers thing level, but those skilled in the art are it is understood that in other test item of chemical analysis field, be suitable for too, such as detect waste oil label, because in waste oil, component is various, need to find out the label with reference value, by method provided by the present invention, calculate DI value, the label with reference value can be obtained, thus whether diagnosis is waste oil.
The foregoing is only preferred embodiment of the present invention; not thereby embodiments of the present invention and protection domain is limited; to those skilled in the art; should recognize and all should be included in the scheme that equivalent replacement done by all utilizations instructions of the present invention and diagramatic content and apparent change obtain in protection scope of the present invention.
Claims (3)
1. a method for evaluation mark thing level, is characterized in that, comprises the following steps:
Step 1: determine label kind to be evaluated;
Step 2: multiple experimental group is set, each experimental group all selects abnormal group and control group as research object;
Step 3: the marker data gathering research object described in multiple experimental group; Setting the level of each marker data in abnormal group in each experimental group is X
1be X with the level in control group
2;
Step 4: the marker data of the exception group in described each experimental group and control group is carried out the test with statistical significance number of times, averages respectively and obtain
with
and calculate standard error SEM respectively
1and SEM
2, merge described standard deviation, computing formula is
Step 5: calculate the standardization difference in means SMD at abnormal group and control group of each label factor of influence in each experimental group, computing formula is
Step 6: use I
2the method of statistic calculates the heterogeneous difference I of each label level between different experiments group
2;
Step 7: the evaluation number DI calculating each label level, computing formula is DI=|SMD|-I
2;
For analyzing the standardization difference in means SMD at abnormal group and control group of each label factor of influence in each experimental group under random-effect model in described step 5.
2. the method for evaluation mark thing level according to claim 1, it is characterized in that, in described step 2, experimental group is at least 2 groups.
3. the method for evaluation mark thing level according to claim 1, is characterized in that, in described step 7, DI is less than 0 for low value, is more than or equal to 0 and is less than or equal to 1 for medium value, being greater than 1 for high value.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210313089.8A CN102831322B (en) | 2012-08-29 | 2012-08-29 | A kind of method of evaluation mark thing level |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210313089.8A CN102831322B (en) | 2012-08-29 | 2012-08-29 | A kind of method of evaluation mark thing level |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102831322A CN102831322A (en) | 2012-12-19 |
| CN102831322B true CN102831322B (en) | 2016-04-06 |
Family
ID=47334455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210313089.8A Expired - Fee Related CN102831322B (en) | 2012-08-29 | 2012-08-29 | A kind of method of evaluation mark thing level |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102831322B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103310129B (en) * | 2013-06-13 | 2017-03-01 | 浙江大学 | Evidential gastric cancer prognosis molecule label screening technique |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1964986A (en) * | 2003-10-07 | 2007-05-16 | 千年药品公司 | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
-
2012
- 2012-08-29 CN CN201210313089.8A patent/CN102831322B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1964986A (en) * | 2003-10-07 | 2007-05-16 | 千年药品公司 | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
Non-Patent Citations (3)
| Title |
|---|
| 事件相关电位P300在精神分裂症中的诊断价值;仇瑶琴;《中国博士学位论文全文数据库-医药卫生科技辑》;20110915(第09期);E071-11 * |
| 抗高血压药物临床试验疗效评价方法研究;许林勇;《中国博士学位论文全文数据库-医药卫生科技辑》;20081215(第12期);E062-68 * |
| 曲美他嗪治疗慢性心力衰竭随机对照研究的Meta分析;彭澍;《循证医学》;20110831;第11卷(第4期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102831322A (en) | 2012-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harrison et al. | Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen | |
| Berbari et al. | Inflammatory blood laboratory levels as markers of prosthetic joint infection: a systematic review and meta-analysis | |
| Zhu et al. | Sensitivity, specificity, accuracy, associated confidence interval and ROC analysis with practical SAS implementations | |
| Leroy et al. | Association of procalcitonin with acute pyelonephritis and renal scars in pediatric UTI | |
| Rossi et al. | Comparison of tracheal wash and bronchoalveolar lavage cytology in 154 horses with and without respiratory signs in a referral hospital over 2009− 2015 | |
| CN109030803B (en) | Biochemical detection quality control method | |
| RU2019125313A (en) | COMPUTER-REALIZED METHOD AND PORTABLE DEVICE FOR ANALYSIS OF GLUCOSE CONTROL DATA SHOWING THE LEVEL OF GLUCOSE IN PHYSIOLOGICAL FLUID | |
| Murguía-Romero et al. | The body mass index (BMI) as a public health tool to predict metabolic syndrome | |
| CN110272990A (en) | Excretion body microRNA is as depression marker and its application | |
| Moriarty et al. | Evaluating implementation of a rapid response team: considering alternative outcome measures | |
| CN101246113B (en) | Monitoring method for hemoglobin test result | |
| CN102831322B (en) | A kind of method of evaluation mark thing level | |
| CN111260495A (en) | Grain sampling method, readable storage medium and system | |
| Jeong et al. | Global burden of gout in 1990–2019: A systematic analysis of the Global Burden of Disease Study 2019 | |
| EP2611358B1 (en) | System and apparatus for automatically diagnosing emphysema | |
| JP2006235940A (en) | Health management support system | |
| Chalmers et al. | Correlation of aspiration results with periprosthetic sepsis in revision total hip arthroplasty | |
| CN101125084A (en) | Fault-tolerant method and device in respiratory mechanics monitoring system | |
| Stavngaard et al. | Quantitative assessment of regional emphysema distribution in patients with chronic obstructive pulmonary disease (COPD) | |
| Paradisi et al. | An empirical estimate of the infection fatality rate of COVID-19 from the first Italian outbreak | |
| Ikeokwu et al. | Unveiling the impact of COVID-19 vaccines: A meta-analysis of survival rates among patients in the United States based on vaccination status | |
| Sunkara et al. | The colorectal cancer mortality-to-incidence ratio as a potential cancer surveillance measure in Asia | |
| McEneaney et al. | Video instructions improve accuracy of self-measures of waist circumference compared with written instructions | |
| CN105277723B (en) | A kind of detecting system of glomerular filtration rate | |
| CN101125083A (en) | Fault-tolerant method and device in respiratory mechanics monitoring system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160406 Termination date: 20200829 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |